Can NeoVista’s Epimacular Brachytherapy Improve Treatment of Macular Degeneration?

October 17, 2010

At the American Academy of Ophthalmology meeting, NeoVista made public the one-year results from their MERITAGE Study. This study was designed to examine NeoVista’s Epimacular Brachytherapy procedure when used in patients who require chronic therapy with anti-VEGF agents on an ongoing basis to control Neovascular Age-Related Macular Degeneration (Wet AMD).

Study results to date suggest that a single procedure of Epimacular Brachytherapy can stabilize visual acuity in a majority of wet AMD patients (79%) while decreasing the number of anti-VEGF injections required. Most
importantly, 47% of patients enrolled in the study experienced some improvement in their visual acuity while 10% of patients gained 15 or more letters of visual acuity at 12 months. This improvement is significant in patients that had been receiving chronic anti-VEGF treatment with no vision improvement in the year prior to enrollment.

Read the full release.




Jump down to form below to submit your own comments

Trackback URL

Have insights to contribute? Please submit your comment below